Table 2.
Notable therapies administered to patients with COVID-19 ARDS or historical ARDS control subjects
| COVID-19 ARDS (n = 27) |
Viral ARDS (n = 14) |
Bacterial ARDS (n = 21) | Culture-Negative ARDS (n = 30) | P Value | |
|---|---|---|---|---|---|
| Gas exchange rescue | |||||
| Prone positioning | 19 (70.4) | 4 (28.6) | 1 (4.8) | 2 (6.7) | <0.01 |
| Neuromuscular blockade | 20 (74.1) | 4 (28.6) | 6 (28.6) | 8 (26.7) | <0.01 |
| Inhaled vasodilators | 5 (18.5) | 0 (0.0) | 2 (9.5) | 4 (13.3) | 0.37 |
| ECMO | 7 (28.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | <0.01 |
| ARDS supportive care | |||||
| Therapeutic anticoagulation | 10 (37.0) | 6 (42.9) | 8 (38.1) | 10 (33.3) | 0.94 |
| Continuous renal replacement therapy | 7 (25.9) | 3 (21.4) | 5 (23.8) | 7 (23.3) | 0.99 |
| Corticosteroids | 14 (51.9) | 8 (57.1) | 7 (33.3) | 9 (30.0) | 0.19 |
| COVID-19 therapeutics | |||||
| Hydroxychloroquine | 2 (13.3) | N/A | N/A | N/A | N/A |
| Remdesivir | 15 (55.5) | N/A | N/A | N/A | N/A |
| Convalescent plasma | 10 (37.0) | N/A | N/A | N/A | N/A |
Definition of abbreviations: ARDS = acute respiratory distress syndrome; COVID-19 = coronavirus disease; ECMO = extracorporeal membrane oxygenation; N/A = not applicable.
Data are shown as n (%).